Clinical evidence of improved biocompatibility using heparin-coated surfaces

Perfusion

Volumn 11, Issue 3, 1996, Pages 264-269

  Matheve, Christiaan ^a,b  

^a Medtronic Cardiac Surg C   (United Kingdom)

^b Medtronic Cardiopulmonary Division   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

BIOCOMPATIBILITY; BLOOD; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0029797579     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100312     Document Type: Conference Paper

References (14)

1. Lindahl U et al. More to heparin than anti-coagulation. Thromb Res 1994; 75: 1-32.
2. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-50.
3. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Art Org 1983; 11 (2,3): 161-73.
4. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1983; 86: 845-57.
5. Mollnes TE, Fosse E. The complement system in trauma-related and ischaemic tissue damage: a brief review. Shock 1994; 2(4): 301-10.
6. Casey LC. Role of cytokine in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993; 56: S92-96.
7. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res 1995; 29: 655-61.
8. Wendel HP, Heller W, Gallimore MJ, Hoffmeister HE. Heparin-coated oxygenators significantly reduce contact system activation in an in-vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis 1994; 5: 673-78.
9. Steinberg BM, Gross EA, Schwartz DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 525-29.
10. Shigemitsu O, Hadama T, Takasaki H et al. The clinical study of a heparin-bonded membrane oxygenator (Carmeda Maxima). Jpn J Artif Organs 1993; 22(3): 890-94.
11. Wheeldon DR, Bethune DW, Gill RD. Vortex pumping for routine cardiac surgery: a comparative study. Perfusion 1990; 5: 135-43.
12. Berki T, Gurbuz A, Isik O et al. Cardiopulmonary bypass using a centrifugal pump. Vasc Surg 1992; 26(2): 123-34.
13. Jacob H, Hafner G, Iversen S et al. Reoperation and the centrifugal pump? Eur J Cardiothorac Surg 1992; 6 (suppl 1): S59-S63.
14. Hatori N, Yoshizu H, Haga Y et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. J Artif Organs 1994; 18(12): 904-10.